Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression

Table 1 Clinical characteristics of 111 cases of hepatocellular carcinoma patients after liver transplantation

Characteristics		Number of cases	Percentage of cases (%)
Age (year)	< 60	78	70.3
	≥ 60	33	29.7
Gender	Male	93	83.8
	Female	18	16.2
Hepatitis	HBV	89	80.2
	HCV	13	11.7
	None	9	8.1
Cirrhosis	Y	109	98.2
	N	2	1.8
AFP (ug/L)	< 400	71	64
	≥ 400	40	36
Meld score	≤ 14	108	97.3
	15-18	3	2.7
	> 18	0	0
Clinicopathological stag	I	27	24.3
	II	34	30.6
	III	50	45.1
	IV	0	0
MVI	Y	28	25.2
	N	83	74.8
Pathological differentiation	Well	1	0.9
	Moderate	69	62.1
	Poor	33	29.7
	Undifferentiated	8	7.2
Number of tumors	Single	48	43.2
	Multiple	63	56.8
Satellite nodules	N	88	79.3
	Y	23	20.7
Relapse states (at follow-up)	N	69	62.2
	Y	42	37.8
Vital states (at follow-up)	Alive	81	73
	Dead	30	27
Expression of ASH1L	Low expression	67	60.4
	High expression	44	39.6

AFP: Alpha-fetoprotein; MVI: Microvascular invasion; HBV: Hepatitis B virus; HCV: Hepatitis C virus; Y: Yes; N: No.